Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7536 | 0.97 | — | — | |
| Fluoride SCHEMBL29026731 | 0.94 | ALDH1A1 (0.50) | ALDH1A1TRPA1TSHRCYP2A6TAAR1 | |
| SCHEMBL27518670 | 0.94 | ALDH1A1 (0.50) | ALDH1A1TRPA1TSHRCYP2A6TAAR1 | |
| Ammonia Solution, Strong SCHEMBL28228784 | 0.94 | ALDH1A1 (0.50) | ALDH1A1TRPA1TSHRCYP2A6TAAR1 | |
| Bromide SCHEMBL29227177 | 0.94 | ALDH1A1 (0.50) | ALDH1A1TRPA1TSHRCYP2A6TAAR1 | |
| Phosphine SCHEMBL27726130 | 0.94 | ALDH1A1 (0.50) | ALDH1A1TRPA1TSHRCYP2A6TAAR1 | |
| SCHEMBL3362246 | 0.88 | ALDH1A1 (0.50) | ALDH1A1TRPA1TSHRCYP2A6TAAR1 | |
| Iodomethane SCHEMBL8216911 | 0.88 | ALDH1A1 (0.46) | ALDH1A1TRPA1TSHRCYP2A6TAAR1 | |
| SCHEMBL131361 | 0.83 | ALDH1A1 (0.67) | ALDH1A1TRPA1TSHRTAAR1HTR2A | |
| SCHEMBL6764664 | 0.82 | ALDH1A1 (0.47) | ALDH1A1TRPA1TSHRCYP2A6TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160212-A | Organic luminescent material and preparation method and application thereof | 吉林奥来德光电材料股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3891148-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020114494-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| WO-2013185740-A1 | A METHOD FOR THE PREPARATION OF FINGOLIMOD | ZENTIVA, K.S. (CZ) | 2013-12-19 | — | — | WO | disclosed |
| CN-101074242-A | Cells accumulation for sphosphonate analogs of HIV protease inhibitor compound and the same compound | GILEAD SCIENCES INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-1313472-C | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2007-05-02 | — | — | CN | disclosed |
| US-7186830-B2 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1474424-A4 | TRICYCLIC 2-PYRIMIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-6844340-B2 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040266778-A1 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | TARBY CHRISTINE M | 2004-12-30 | — | — | US | disclosed |
| EP-1474424-A1 | TRICYCLIC 2-PYRIMIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030162800-A1 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003062238-A1 | TRICYCLIC 2-PYRIMIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162800-A1 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | TYMP, TYMS, DPYD | ALDH1A1 413/4885TRPA1 4758/4885TSHR 3653/4885 |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RET, SLC10A2, REL | ALDH1A1 2416/4885TRPA1 496/4885TSHR 2826/4885 |
| US-20040266778-A1 | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors | TYMP, TYMS, DPYD | ALDH1A1 413/4885TRPA1 4758/4885TSHR 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.